DBV Technologies S.A.

NasdaqCM DBVT

DBV Technologies S.A. Return on Assets (ROA) for the year ending December 31, 2023: -39.74%

DBV Technologies S.A. Return on Assets (ROA) is -39.74% for the year ending December 31, 2023, a -1.73% change year over year. Return on assets measures profitability against assets; higher ROA indicates efficient asset use and profitability.

DBV Technologies S.A. Return on Assets (ROA) for the year ending December 31, 2022 was -39.07%, a 41.40% change year over year.
DBV Technologies S.A. Return on Assets (ROA) for the year ending December 31, 2021 was -66.66%, a -13.74% change year over year.
DBV Technologies S.A. Return on Assets (ROA) for the year ending December 31, 2020 was -58.61%, a 7.85% change year over year.
DBV Technologies S.A. Return on Assets (ROA) for the year ending December 31, 2019 was -63.60%, a 34.22% change year over year.

Key data

Date	Return on Assets (ROA)	Return on Equity (ROE)	Return on Capital Employed (ROCE)	Interest Coverage Ratio

NasdaqCM: DBVT

DBV Technologies S.A.

CEO	Mr. Daniel Tassé
IPO Date	Oct. 22, 2014
Location	France
Headquarters	177-181 Avenue Pierre Brossolette
Employees	108
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals Vaccines

Description

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The milk-induced company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA); Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

Key trends

Past 5 years